Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy [Ya...
Oculis Holding AG (OCS)
Company Research
Source: Yahoo! Finance
Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trial Rapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43 Licaminlimab was well tolerated similar to vehicle Company plans to finalize Phase 3 development plans following an End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) An investor and analyst webcast will be held today at 8:30am US Eastern Time Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFa biologic eye drop with an established dual anti-inflammatory
Show less
Read more
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG news events
Weekly update
A roundup of the hottest topics
OCS
News
- Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.MarketBeat
- Oculis Holding AG (NASDAQ: OCS) had its price target raised by analysts at HC Wainwright from $28.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at Bank of America Co. from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Oculis Holding AG (NASDAQ: OCS) had its price target raised by analysts at Robert W. Baird from $35.00 to $37.00. They now have an "outperform" rating on the stock.MarketBeat
- Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine StrategyGlobeNewswire
OCS
Sec Filings
- 6/10/24 - Form 6-K
- 5/31/24 - Form 6-K
- 5/8/24 - Form 6-K
- OCS's page on the SEC website